Differences in peripheral blood mononuclear cell (PBMC) proteomes. Venn diagrams illustrate the extent of overlapping of identified proteins between control (Ctr) and stroke (Str) groups (A and C, total and nascent proteomes, respectively). Numbers are the number of proteins identified by mass spectrometry. Heat maps present results of hierarchical clustering analysis, showing distances among 4 study groups in PBMC total (B) or nascent (D) proteomes. Color codes in heat maps: red and green—low and high protein abundances, respectively; gray—no protein identification. F indicates female; and M, male.
Differences in peripheral blood mononuclear cell (PBMC) proteomes. Venn diagrams illustrate the extent of overlapping of identified proteins between control (Ctr) and stroke (Str) groups (A and C, total and nascent proteomes, respectively). Numbers are the number of proteins identified by mass spectrometry. Heat maps present results of hierarchical clustering analysis, showing distances among 4 study groups in PBMC total (B) or nascent (D) proteomes. Color codes in heat maps: red and green—low and high protein abundances, respectively; gray—no protein identification. F indicates female; and M, male.
Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini and Thomas A. Kent
Stroke. 2013;44:1525-1531, originally published May 24, 2013
Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. Kent
Stroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116
Good clinical outcome at 90 days for National Institute of Neurological Disorders and Stroke (NINDS) race-by-sex subgroups relative to the pPREDICTS natural history model of acute ischemic stroke. The pPREDICTS outcome model shows percentage of subjects achieving modified Rankin Score (mRS) ≤2 based on baseline NIHSS and age. The NINDS subgroup results are superimposed on the model at the corresponding baseline NIHSS and age. Placebo outcomes were close to the predicted model for all subgroups (proximity of the control results to the middle outcome surface). Significant improvement with recombinant tissue-type plasminogen activator (rtPA) was seen for both white sexes (A; both rtPA outcomes are above the P=0.05 interval). Black men showed improvement with rtPA that was only slightly below the P=0.05 interval. However, there was no improvement for black women (arrow; B). Although the percentage that achieved an mRS of 0–2 was higher in the rtPA-treated black women group, this increase can be accounted for by baseline imbalance that favored better outcomes. NIHSS indicates National Institutes of Health Stroke Scale.
Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. Kent
Stroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116
